JUVENESCENCE
16.1.2023 10:01:37 CET | Business Wire | Press release
Juvenescence has named Dr Richard Marshall CBE as its new CEO, effective 16 January 2023. Dr Marshall succeeds co-founder Dr Gregory Bailey, who will remain on the company’s board as Executive Chairman.
Dr Marshall brings over twenty years of business leadership to the company, with fifteen years at GSK culminating in his position as Vice President, Head of the Fibrosis & Lung Injury Discovery Performance Unit (DPU). Most recently, Dr Marshall was Senior Vice President, Global Development Head, Respiratory & Immunology of AstraZeneca. Dr Marshall was awarded a CBE in the 2021 Queen’s Honours List for his contribution to UK science and COVID-19.
“I am delighted that Dr Richard Marshall CBE, the former Senior Vice-President, Global Head of Development, Respiratory & Immunology at AstraZeneca, has agreed to lead Juvenescence as CEO. Throughout his career, Richard has been the architect of numerous transformative R&D strategies to drive innovation and deliver rapid growth, with a track record of collegial success, building high performing teams and developing novel therapies,” outgoing CEO Dr Gregory Bailey said. “Richard is a results-oriented leader who believes that in a post-COVID-19 world facing the impending crisis of an inverted demographic pyramid coupled with undercapitalized pension funds and ever-increasing healthcare costs, proactive, decentralized solutions are desperately needed. Juvenescence is a critical player in the mega-trends now driving towards the healthier lifestyles and digital health strategies needed to confront these issues. I am confident that with this appointment, we have a world class team with the experience and skillset to position Juvenescence as one of the premier biotech and pharmaceutical companies focused on modifying aging through prevention.”
Dr Richard Marshall CBE said, “I am thrilled to be joining Juvenescence at such a pivotal point in the company’s history. They are at a real inflection point, with an incredible opportunity to build on Juvenescence’s trusted brand and the Founders’ 30-year history of developing drugs to bring innovative approaches to modify and prevent the impact of aging to the market. With its broad portfolio and depth of experience, Juvenescence is building a unique ecosystem of key partnerships and acquiring the critical capabilities needed for success in this rapidly evolving field. I look forward to working with the team, our partners, and shareholders to capitalize on this incredible opportunity.”
About Juvenescence
Juvenescence is a life sciences company developing therapies to modify aging and increase healthy human lifespan. It was founded by Jim Mellon, Dr Greg Bailey and Dr Declan Doogan. The Juvenescence team consists of highly experienced drug developers, entrepreneurs, marketers, and investors with a significant history of success in pharmaceutical drug development, synthetic biology, and tissue and cellular engineering.
Juvenescence has a broad portfolio of products in development and is driving innovation, with a focus on discovering and developing these therapies to modify the aging process, through prevention and by regenerating damage, to support healthy aging and increase health span. The company is committed to inspiring and equipping the world to, not just reimagine what it means to age, but to help people Reimagine A Lifetime. For more information see: www.JuvLabs.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005022/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Techtronic Industries Delivers Solid Performance in 20253.3.2026 14:41:00 CET | Press release
Growing Sales to US$15.3 Billion, Net Profit Increased to US$1.2 Billion Techtronic Industries Co. Ltd. (“TTI” or the “Company”) (stock code: HK:0669, ADR symbol: TTNDY), a global cordless power tool, outdoor power equipment and floorcare & cleaning company, is pleased to announce the audited consolidated results of the Company and its subsidiaries for the year ended December 31, 2025. TTI delivered record sales of US$15.3 billion in 2025, growing 4.4% on a reported basis and 4.1% in local currency. Our two leading brands, MILWAUKEE and RYOBI, both delivered solid performances in 2025 with MILWAUKEE growing 7.9% and RYOBI growing 5.4% in local currency. TTI delivered record sales and earnings despite significant tariff headwinds, growing sales 4.4% to US$15.3 billion and net profit 6.8% to US$1.2 billion. Our Global MILWAUKEE business grew 8.1% on a reported basis with underlying sales rising 10.3% in local currency (excluding the discretionary suspension of certain second half promoti
Quectel and MediaTek Unveil Next Generation 5G-A and Wi-Fi 8 Intelligent CPE Reference Design at MWC 20263.3.2026 14:38:00 CET | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the launch of a new intelligent CPE reference design based on the MediaTek T930 platform, integrating 5G-Advanced and Wi-Fi 8 technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303124613/en/ Quectel and MediaTek unveil next generation 5G-A and Wi-Fi 8 intelligent CPE reference design at MWC 2026 The solution combines the high-performance 5G-A connectivity, intelligent reliability and advanced capabilities of the MediaTek T930 platform with Quectel’s deep expertise in the global Fixed Wireless Access (FWA) market. Moving beyond a simple focus on high speed, it delivers a fully integrated, all-in-one solution featuring exceptional performance, ultra-high stability, and intelligent network management. Designed for both residential and enterprise users, the solution enables transformative improvements in broadband access, mobile
The Progeria Research Foundation and Forge Biologics Announce Manufacturing Partnership to Advance Gene Therapy for Children with Progeria3.3.2026 14:00:00 CET | Press release
Partnership marks a critical step toward clinical development of an AAV gene therapy using a base editing approach designed to target the genetic cause of Hutchinson-Gilford Progeria SyndromeForge Biologics will provide process development and manufacturing expertise to support gene therapy advancement led by world-renowned researchers Leslie Gordon, David Liu, and Francis Collins The Progeria Research Foundation (“PRF”), a nonprofit research organization dedicated to developing treatments and the cure for Hutchinson-Gilford Progeria Syndrome (“Progeria”), and Forge Biologics, (“Forge”), a leading manufacturer of gene therapies and member of the Ajinomoto Bio-Pharma Services group, today announced a manufacturing agreement to support the development and manufacturing of SamPro-2, PRF’s investigational gene therapy for children and young adults living with Progeria, an ultrarare and fatal genetic disease characterized by rapid aging. This press release features multimedia. View the full
PAX Unveils Long-Anticipated PAX FOUR, Its Most Powerful Dry Herb Vaporizer Yet3.3.2026 14:00:00 CET | Press release
Designed for denser vapor and immediate impact without combustion, FOUR delivers smoking-level intensity in a precision-engineered, portable device Nearly two decades after defining the category, PAX today announced the launch of PAX FOUR, the most powerful dry herb vaporizer in the company’s history. Built for consumers who want dense vapor and immediate impact without combustion, PAX FOUR delivers smoking-level intensity you can see and feel in a sleek, precision-engineered device. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303740648/en/ PAX FOUR, the most powerful dry herb vaporizer in the company’s history. The cannabis vaporization category continues to grow as consumers shift away from smoking and combustion, yet many remain loyal to traditional smoking methods, often citing weak vapor, lack of intensity, and inconsistent performance from existing devices. PAX FOUR was engineered to change that — producing large
Riskified Announces Expansion of AI Agent Intelligence to Secure Native Merchant AI Shopping Assistants3.3.2026 14:00:00 CET | Press release
Amidst the growing adoption of native AI agents and chatbots on retail websites, Riskified leverages its unique data infrastructure to help merchants deploy highly personalized, secure AI shopping assistants Riskified (NYSE: RSKD), a leader in ecommerce fraud and risk intelligence, today announced an expansion of its AI Agent Intelligence platform, positioning the company as the definitive shield for the next era of ecommerce. As merchants explore deploying their own native, conversational AI shopping assistants to elevate their customer experience, Riskified is ensuring that these new touchpoints are protected from sophisticated fraud and abuse. Retailers are heavily investing in bringing AI agents directly to their digital storefronts. Research from McKinsey & Company underscores this trend, noting that 82% of retail organizations have already launched generative AI pilots focused on reinventing customer service. As merchants build out their AI shopping assistants to offer deep perso
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom